Komori
KYORIN Pharmaceutical (4569) · TargetRestated

Executing “HOPE100 – Stage 3 –”

First written in FY2020. 8 of 10 entries say "Restated". Latest entry: FY2025-H1.

10entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2020 – FY2023-Q1ReframedFY20232020: 320202021: 320212022: 220222023: 120232024: 12024
Same theme, other companies
Phased expansion from the long-term vision HOPE100 to Vision 110A theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2025-H1RestatedAnnual report

    「The Group is working to achieve the long-term vision Vision 110 (fiscal 2023 to fiscal 2032) and the medium-term management plan Vision 110—Stage 1—(fiscal 2023 to fiscal 2025), formulated in fiscal 2023.」

    Vision 110 and Stage 1 continue as plans for fiscal 2023 through fiscal 2032 and fiscal 2023 through fiscal 2025, respectively.
  2. FY2023ReframedAnnual report

    「In light of these circumstances, in fiscal 2023, when the Company celebrates its 100th anniversary, the Group decided to renew its organisational structure, end the long-term vision HOPE100 one year ahead of schedule, and formulate and launch the new long-term vision Vision 110 and the new medium-term management plan Vision 110—Stage 1—.」

    HOPE100—Stage 3—was ended one year ahead of schedule in light of changes in the external and internal environment, and the Group moved to Vision 110 and Stage 1.
  3. FY2023-Q1RestatedAnnual report

    「With the aim of realizing the long-term vision, “HOPE100,” the Group operates under the medium-term management plan, “HOPE100—Stage 3—(FY2020–FY2023),” launched in the fiscal year ending March 2021.」

    Stage 3 continues to be executed for fiscal 2020 through fiscal 2023.
  4. FY2022-Q3RestatedAnnual report

    「Against this backdrop, the Group operates under the medium-term management plan, “HOPE100—Stage 3—(FY2020–FY2023),” launched in the fiscal year ending March 2021, with the aim of realizing the long-term vision, “HOPE100.”」

    Stage 3 continues as the medium-term management plan for fiscal 2020 through fiscal 2023.
  5. FY2022-Q2RestatedAnnual report

    「Under the medium-term management plan HOPE100—Stage 3—(fiscal 2020 to fiscal 2023), launched in the fiscal year ending March 2021,」

    Stage 3 continues to be executed for fiscal 2020 through fiscal 2023.
  6. FY2022-Q1RestatedAnnual report

    「Under the medium-term management plan HOPE100—Stage 3—(fiscal 2020 to fiscal 2023), launched in the fiscal year ending March 2021,」

    Stage 3 continues to be executed for fiscal 2020 through fiscal 2023.
  7. FY2021-Q3RestatedAnnual report

    「To achieve the long-term vision HOPE100 (through fiscal 2023), the Group is operating under the new medium-term management plan HOPE100—Stage 3—(fiscal 2020 to fiscal 2023), which began this fiscal year.」

    Stage 3, the final phase of HOPE100, continues as the plan for fiscal 2020 through fiscal 2023.
  8. FY2021-Q2RestatedAnnual report

    「Against this backdrop, the Group launched the new medium-term management plan, “HOPE100—Stage 3—(FY2020–FY2023),” this fiscal year with the aim of realizing the long-term vision, “HOPE100.”」

    Stage 3 continues its business operations as the medium-term management plan for fiscal 2020 through fiscal 2023.
  9. FY2021-Q1RestatedAnnual report

    「Against this backdrop, the Group launched the new medium-term management plan, “HOPE100—Stage 3—(FY2020–FY2023),” this fiscal year with the aim of realizing the long-term vision, “HOPE100.”」

    Stage 3 began its first year of business operations as the medium-term management plan for fiscal 2020 through fiscal 2023.
  10. FY2020First statedAnnual report

    「In FY2020, we launched the medium-term management plan, “HOPE100 – Stage 3 – (FY2020–FY2023),” the final phase of the long-term vision. Under the new medium-term management plan, we will work to achieve sustainable growth and enhance corporate value over the medium to long term.」

    After Stage 2 ended, the final-phase plan for the long-term vision, covering FY2020 through FY2023, was launched.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Executing “HOPE100 – Stage 3 –” | KYORIN Pharmaceutical Co.,Ltd. (4569) | Komori